Results 261 to 270 of about 319,649 (342)

Comparison of different equations for estimating the glomerular filtration rate in pediatric kidney transplant recipients. [PDF]

Pediatr Nephrol
Sukboonthong P, Pooliam J, Jantongsree M, Sumboonnanonda A, Pattaragarn A, Supavekin S, Piyaphanee N, Lomjansook K, Thunsiribuddhichai Y, Tinnabut I, Khueankong N, Chaiyapak T.   +11 more
europepmc   +1 more source

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Sex-specific glomerular filtration rate changes in response to acute hemoglobin exposure. [PDF]

Biomed Pharmacother
Lucas D, R Muller C, Munoz C, O'Boyle Q, Palmer AF, Cabrales P.   +5 more
europepmc   +1 more source

Harmonized Tubular Maximum Phosphate reabsorption per Glomerular Filtration Rate reporting in adults and children in Australia and New Zealand. [PDF]

JBMR Plus
Chiang C, Choy KW, Coates P, Carrivick S, Farrell CJ, Clifton-Bligh RJ, Lim EM.   +6 more
europepmc   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Changes in estimated glomerular filtration rate after percutaneous nephrolithotomy in patients with stage 2-4 chronic kidney disease. [PDF]

Urol Ann
Faddan AHA, Abdelghany M, Kurkar A, Moeen AM, Gadalla MA.   +4 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Estimated Glomerular Filtration Rate and Incident Prediabetes Risk in Normoglycemic Adults With Parental Type 2 Diabetes. [PDF]

J Endocr Soc
Brawley B, Brown L, Asuzu P, Dagogo-Jack S.   +3 more
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate. [PDF]

Fundam Clin Pharmacol
Liabeuf S, Berdougo-Tritz J, Augey L, Mbarek A, Jadoul M, Deray G, Massy ZA.   +6 more
europepmc   +1 more source